Arbutus Biopharma Corp

ABUS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-84.4M $-384.2M $-62.7M $-38.8M $-14.1M $29.6M $-10.1M
Depreciation & Amortization
Depreciation $2.0M $1.1M $589.0K $529.0K $613.0K $866.0K $986.9K
Amortization
Stock-Based Compensation $15.1M $903.0K $982.3K $633.4K
Net Cash from Operating Activities $-48.6M $-57.9M $-56.4M $-12.4M $-6.7M $32.9M $-7.8M
Investing Activities
Capital Expenditures $7.3M $4.0M $2.3M $1.1M $725.0K $15.0K $60.4K
Business Acquisitions
Net Cash from Investing Activities $27.8M $-99.1M $7.7M $-43.0M $-725.0K $-12.0K $-60.4K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $49.3M $12.6M $143.9M $60.7M $32.7M $4.5M $4.6M
Net Change in Cash $30.9M $-143.4M $94.6M $3.5M $21.7M $38.0M $-3.4M
Free Cash Flow $-55.9M $-61.9M $-58.7M $-13.5M $-7.5M $32.9M $-7.9M
← Newer Page 2 of 2 Older →